- Home
- FMBH vs ELVN Comparison
FMBH vs ELVN Comparison
Compare FMBH & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMBH
- ELVN
- Stock Information
- Founded
- FMBH 1865
- ELVN 2016
- Country
- FMBH United States
- ELVN United States
- Employees
- FMBH N/A
- ELVN N/A
- Industry
- FMBH Major Banks
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- FMBH Finance
- ELVN Health Care
- Exchange
- FMBH Nasdaq
- ELVN Nasdaq
- Market Cap
- FMBH 974.1M
- ELVN 1.2B
- IPO Year
- FMBH N/A
- ELVN 2020
- Fundamental
- Price
- FMBH $36.30
- ELVN $21.43
- Analyst Decision
- FMBH Hold
- ELVN Strong Buy
- Analyst Count
- FMBH 5
- ELVN 5
- Target Price
- FMBH $43.40
- ELVN $41.20
- AVG Volume (30 Days)
- FMBH 61.0K
- ELVN 542.6K
- Earning Date
- FMBH 10-30-2025
- ELVN 11-12-2025
- Dividend Yield
- FMBH 2.76%
- ELVN N/A
- EPS Growth
- FMBH 13.11
- ELVN N/A
- EPS
- FMBH 3.52
- ELVN N/A
- Revenue
- FMBH $328,480,000.00
- ELVN N/A
- Revenue This Year
- FMBH N/A
- ELVN N/A
- Revenue Next Year
- FMBH $4.20
- ELVN $20.05
- P/E Ratio
- FMBH $10.29
- ELVN N/A
- Revenue Growth
- FMBH 7.81
- ELVN N/A
- 52 Week Low
- FMBH $27.58
- ELVN $13.30
- 52 Week High
- FMBH $43.86
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- FMBH 30.69
- ELVN 60.82
- Support Level
- FMBH $36.47
- ELVN $19.02
- Resistance Level
- FMBH $38.01
- ELVN $20.66
- Average True Range (ATR)
- FMBH 0.85
- ELVN 1.03
- MACD
- FMBH -0.25
- ELVN 0.18
- Stochastic Oscillator
- FMBH 5.54
- ELVN 93.43
About FMBH First Mid Bancshares Inc.
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.